Safety and Efficacy of Pluripotent Stem Cell-derived Mesenchymal Stem Cell Exosome (PSC-MSC-Exo) Eye Drops Treatment for Dry Eye Diseases Post Refractive Surgery and Associated With Blepharospasm

Dry Eye Disease Clinical Trial

Official title:
A Clinical Study of the Safety and Efficacy of Pluripotent Stem Cell-derived Mesenchymal Stem Cell Exosome (PSC-MSC-Exo) Eye Drops Treatment for Dry Eye Diseases Post Refractive Surgery and Associated With Blepharospasm

Status Not yet recruiting

Clinical Trial Summary

The purpose of this study is to evaluate the preliminary safety and effectiveness of Pluripotent Stem Cell-derived Mesenchymal Stem Cell Exosome (PSC-MSC-Exo) Eye Drops in the treatment of dry eye diseases post refractive surgery and associated with blepharospasm

Clinical Trial Description

Dry eye disease (DED) is a multifactorial disease of the ocular surface characterized by instability of the tear film and the prevalence has been estimated to reach 20%-40%. Especially, dry eye symptoms are common complaints of patients with blepharospasm or refractive surgery history, seriously affecting their quality of life. There are many conventional therapies for DED which include ocular lubricants, oral essential fatty acid supplementation, lid hygiene and warm compresses, punctal occlusion, various treatments to obstructed meibomian glands, topical antibiotics, topical corticosteroids, topical secretagogues, topical non-glucocorticoid immunomodulatory drugs and scleral contact lenses. However, the overall efficacy is still unsatisfactory with apparent side effects, long periods of treatment, and high-costs. Mesenchymal stem cell-derived exosomes (MSC-Exo) are 30-150nm microvesicles secreted by mesenchymal stem cells (MSCs), which can mediate the therapeutic efficacy of mesenchymal stem cells by the encapsulated proteins, miRNAs and other bioactive substances, and showed potential in the treatment of various diseases. This study aims to evaluate the preliminary safety and effectiveness of PSC-MSC-Exo in the treatment of dry eye diseases post refractive surgery and associated with blepharospasm. This is an open-label, single-arm, before-after study with 12 subjects with dry eye diseases and the history of refractive surgery or blepharospasm. There are 5 visits over the course of 12 weeks. Visit 1: Week-1 Visit 2: Week-2 Visit 3: Week-4 Visit 4: Week-8 Visit 5: Week-12 ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05738629
Study type	Interventional
Source	Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact	Qi Gao, Doc.
Phone	86-15088774002
Email	gaoqi8977@zju.edu.cn
Status	Not yet recruiting
Phase	Phase 1/Phase 2
Start date	March 2023
Completion date	February 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03216096` - Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease	Phase 1
Completed	`NCT05825599` - PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms	N/A
Completed	`NCT04656197` - The Ocular Microbiome in Patients With Dry Eye Disease
Completed	`NCT05031806` - Evaluation of the Safety, Tolerability and Efficacy of iNexin™ for the Treatment of the Signs and Symptoms Associated With Dry Eye Disease	Phase 1
Completed	`NCT03688802` - Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation	Phase 2
Completed	`NCT05213156` - Concentration of Ofloxacin Into the Aqueous Humour of Patients With Dry Eye Disease	Phase 4
Completed	`NCT04548427` - Study to Evaluate the Efficacy and Safety of CKD-352	Phase 3
Completed	`NCT06176651` - Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers	Phase 4
Completed	`NCT02254265` - Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca	Phase 2/Phase 3
Completed	`NCT00395759` - The Visual Effect of an Investigational Artificial Tear in the Tear Layer.	N/A
Completed	`NCT00680108` - A Study to Determine the Safety and Tolerability of Escalating Doses of INS365 Ophthalmic Solution	Phase 2
Recruiting	`NCT06064071` - Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD	N/A
Completed	`NCT04139122` - Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease	Phase 1/Phase 2
Not yet recruiting	`NCT06375343` - Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive®	Phase 1
Completed	`NCT01468168` - A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients	Phase 2
Completed	`NCT01014078` - A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease	Phase 4
Completed	`NCT00799682` - Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z®	Phase 4
Completed	`NCT05082974` - Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Laser-assisted in Situ Keratomileusis (LASIK)	Phase 3
Recruiting	`NCT06146881` - Effectiveness of Diquafosol Prophylactic Therapy to Prevent Dry Eye Disease for Cataract Surgery Patients in Indonesia	Phase 2
Completed	`NCT03292809` - CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)	Phase 2/Phase 3